Orgenesis Inc. · OTC:ORGS

Orgenesis — Investor Presentation (2021)

23 slides from Orgenesis's investor presentation, Feb 5, 2021

  1. Slide 1: Unlocking the Power of Cell and Gene Therapy for All

    Slide 1: Unlocking the Power of Cell and Gene Therapy for All

    Unlocking the Power of Cell and Gene Therapy for All

  2. Slide 2: Forward Looking Statements

    Slide 2: Forward Looking Statements

    Forward Looking Statements This presentation contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended. These forward-looking statements in

  3. Slide 3: Corporate Overview

    Slide 3: Corporate Overview

    Corporate Overview Established in 2011 Orgenesis is a global biotech company working to realize affordable breakthroughs in advanced medicines Publicly traded with a proprietary POCare Platform. (NASDAQ: ORGS) Vision: To unlock the curing potential of cell and gene therapy and make it accessible to

  4. Slide 4: Achievements

    Slide 4: Achievements

    Achievements Built contract development manufacturing organization (CDMO) Masthercell from ~$3 million to >$33 million revenue in 5 years (2014-2019) and sold for $315 million in February 2020 with net proceeds of $127 million Developed a three component POCare Platform as a harmonized framework for

  5. Slide 5: What are Cell & Gene Therapies

    Slide 5: What are Cell & Gene Therapies

    What are Cell & Gene Therapies Traditional biopharmaceutical treatments use proteins for therapeutic applications Cell therapies use manipulated genes and cells for therapeutic applications Autologous cell and gene therapies use a patient’s own cells to create the treatment 5

  6. Slide 6: Cell & Gene Therapies are the Future

    Slide 6: Cell & Gene Therapies are the Future

    Cell & Gene Therapies are the Future Harvesting and manipulating individual (autologous) human cells or cell material that are given back to the patient as therapies has tremendous potential for applications in oncology, immunology, genetic and metabolic disorders, and more. We anticipate that by 20

  7. Slide 7: What’s Holding CGTs Back?

    Slide 7: What’s Holding CGTs Back?

    What’s Holding CGTs Back? Centralized, non-automated processes that are high risk, high cost and have complicated logistics. These innovative drugs ultimately cannot be commercialized because of the complexity and cost. 7

  8. Slide 8: How is Orgenesis Changing This?

    Slide 8: How is Orgenesis Changing This?

    How is Orgenesis Changing This? The Orgenesis POCare Platform overcomes conventional processing challenges by enabling sterile, Automation & scalable onsite processing of CGTs: Harmonization Available: Process development is focused on quality control (QC), regulatory compliance and harmonization of

  9. Slide 9: Quality at the Heart of Everything

    Slide 9: Quality at the Heart of Everything

    Quality at the Heart of Everything Orgenesis puts quality at the heart of the organization with the ambition to “Design Global and Adapt Local” through Global Quality Harmonization standards aimed at ensuring quality comparability across the network and application of good biopharmaceutical practice

  10. Slide 10: POCare Platform

    Slide 10: POCare Platform

    POCare Platform The Orgenesis POCare Platform is built on three components to expedite development and production of advanced medicines. All work is validated for GMP compliance and harmonized for reproducibility. POCare Therapies: Produced at the point of care for better outcomes with drastically l

  11. Slide 11: POCare Therapies Pipeline

    Slide 11: POCare Therapies Pipeline

    POCare Therapies Pipeline IND Enabling Program Indications Preclinical Clinical Trials Clinical Use Studies Immuno-Oncology ORGCAR19 (CD19 CAR-T) B-ALL, Lymphoma MOTC (Metabolic Optimized T-Cells) Lung Cancer; Melanoma DUVAC (Cellular vaccine) Solid Tumors; Pancreatic Cancer ORGCAR19.22 (CD19.22 CAR

  12. Slide 12: Koligo Therapeutics Acquisition

    Slide 12: Koligo Therapeutics Acquisition

    Koligo Therapeutics Acquisition • Treatment for chronic pancreatitis: total pancreatectomy + auto-islet transplant (TP-IAT) KYSLECEL™ • US target patient population ~8000 per year for chronic • US sales authorized under FDA “361” pathway pancreatitis • US pilot stage commercialization at hospitals i

  13. Slide 13: Metabolically Optimized T Cells (MOTC) TILs Therapy – Clinical/Commercial Stage

    Slide 13: Metabolically Optimized T Cells (MOTC) TILs Therapy – Clinical/Commercial Stage

    Metabolically Optimized T Cells (MOTC) TILs Therapy – Clinical/Commercial Stage Adoptive cell therapy (ACT) using Tumor-Infiltrating Lymphocytes (TILs) for metastatic melanoma patients Autologous CD4+ and CD8+ T lymphocytes expanded from tumors in the presence of interleukin-2 (IL-2) alone, or in co

  14. Slide 14: Autologous CD19.22 CAR-T Therapy

    Slide 14: Autologous CD19.22 CAR-T Therapy

    Autologous CD19.22 CAR-T Therapy CD19.22 bispecific Chimeric Antigen Receptor T-Cells (CAR-T) for the treatment of B-lineage acute lymphoblastic leukemia (B-ALL) B-ALL is an aggressive neoplasm of B-lymphocyte precursors that express the pan-B-cell marker CD19 in almost all cases. The therapy target

  15. Slide 15: DUVAC (Dual Vaccination Therapy)

    Slide 15: DUVAC (Dual Vaccination Therapy)

    DUVAC (Dual Vaccination Therapy) Antigen presenting cells based anti-cancer immunotherapy targeting Tumor-Associated Antigens (TAAs) for hard to treat solid tumors Dual vaccine cell-based immunotherapy harnesses the immune system’s natural ability to recognize and react to foreign Tumor- Associated

  16. Slide 16: Licensed Therapeutics and Technology Milestones

    Slide 16: Licensed Therapeutics and Technology Milestones

    Licensed Therapeutics and Technology Milestones H2 2018 2019 2020 08 2018 01 2019 02 2020 Bioxomes for Intracellular Delivery Cell-based Cancer Immunotherapy Partnered for Closed Bioxosome and Redoxome for Liver CAR-T-VAC69 - Ovarian cancer Loop Systems for Cell H1 2018 Disorders and Atopic Dermatit

  17. Slide 17: An Expanding POCare Network

    Slide 17: An Expanding POCare Network

    An Expanding POCare Network Orgenesis Development and Service Centers align with global partners, research institutes and hospitals for an expanding number of research programs and clinical trials Orgenesis Centers Network Hospitals & Partners South America Europe Asia North America (US) Belgium Uni

  18. Slide 18: Bringing Point of Care Processing to the Hospital

    Slide 18: Bringing Point of Care Processing to the Hospital

    Bringing Point of Care Processing to the Hospital Orgenesis takes a stepwise approach to building an easy to scale, complete solution for POCare Therapies to be produced onsite at hospitals with POCare Technologies. Mature POC Center • Multi center, harmonized clinical trials Clinical Collaboration

  19. Slide 19: Orgenesis Mobile Processing Units & Labs (OMPUL)

    Slide 19: Orgenesis Mobile Processing Units & Labs (OMPUL)

    Orgenesis Mobile Processing Units & Labs (OMPUL) Short Setup Small Time Footprint Cost Reduction Modular Viral/Non-Viral Robust Processing Production Capabilities. at PoC Scalable 19

  20. Slide 20: OMPUL = High Margin, Easily Scalable Business Model

    Slide 20: OMPUL = High Margin, Easily Scalable Business Model

    Mobility & Flexibility Automated Operation OMPULS can be built as OMPULS have automated grade A/B or B/C ISO 3 single-use sensors to improve cleanrooms for Current Good monitoring and quality Manufacturing Practice control (QC) with minimal (cGMP) compliant processes operator involvement. that can b

  21. Slide 21: Meet Our Board of Directors

    Slide 21: Meet Our Board of Directors

    Meet Our Board of Directors Vered Caplan Yaron Adler Ashish Nanda Board Chairman & CEO Board Director Board Director Guy Yachin David Sidransky Mario Phillips Board Director Board Director Board Director 21

  22. Slide 22: Financial Highlights

    Slide 22: Financial Highlights

    Financial Highlights Stock Information Listing NASDAQ Symbol ORGS Average Daily Volume (30 Day) 53,960 Share Structure Shares Outstanding (as of 21 September) 22.09 M Market Cap (as of 23 October) $110.03 M Cash & Cash Equivalents $98.10 M Long-Term Debt (at $7/share conversion) $10.30M Ownership of

  23. Slide 23: Vered Caplan | CEO; Investor Relations; Media Relations

    Slide 23: Vered Caplan | CEO; Investor Relations; Media Relations

    Vered Caplan | CEO vered.c@orgenesis.com David Waldman | Investor Relations dwaldman@crescendo-ir.com Beth Willers | Media Relations beth.w@orgenesis.com

Source: Internet Archive copy of ir.orgenesis.com

More decks from Orgenesis Inc.

All 11 Orgenesis decks